This systematic review and dose-response meta-analysis evaluated the efficacy and tolerability of gefapixant for the treatment of adults with refractory or unexplained chronic cough. The main outcome measures included cough frequency, cough severity, cough-specific quality of life, treatment-related adverse events, adverse events leading to discontinuation, and taste-related adverse events. 24-hour, awake, and sleep cough frequencies were measured using the VitaloJAK cough monitor.
- Author Kum E et al.
- Publication JAMA
- Year 2023
- Device Type VitaloJAK
